全文获取类型
收费全文 | 95391篇 |
免费 | 6655篇 |
国内免费 | 2708篇 |
专业分类
耳鼻咽喉 | 688篇 |
儿科学 | 1191篇 |
妇产科学 | 856篇 |
基础医学 | 6874篇 |
口腔科学 | 1581篇 |
临床医学 | 8807篇 |
内科学 | 8323篇 |
皮肤病学 | 914篇 |
神经病学 | 4750篇 |
特种医学 | 2554篇 |
外国民族医学 | 13篇 |
外科学 | 7259篇 |
综合类 | 19766篇 |
现状与发展 | 6篇 |
一般理论 | 4篇 |
预防医学 | 10018篇 |
眼科学 | 1578篇 |
药学 | 12929篇 |
575篇 | |
中国医学 | 12530篇 |
肿瘤学 | 3538篇 |
出版年
2024年 | 304篇 |
2023年 | 1470篇 |
2022年 | 2864篇 |
2021年 | 4019篇 |
2020年 | 3986篇 |
2019年 | 3213篇 |
2018年 | 2928篇 |
2017年 | 3277篇 |
2016年 | 3742篇 |
2015年 | 3272篇 |
2014年 | 7371篇 |
2013年 | 6598篇 |
2012年 | 6135篇 |
2011年 | 6626篇 |
2010年 | 5634篇 |
2009年 | 4399篇 |
2008年 | 4073篇 |
2007年 | 4380篇 |
2006年 | 3943篇 |
2005年 | 3314篇 |
2004年 | 2607篇 |
2003年 | 2413篇 |
2002年 | 1813篇 |
2001年 | 1623篇 |
2000年 | 1305篇 |
1999年 | 1214篇 |
1998年 | 961篇 |
1997年 | 866篇 |
1996年 | 744篇 |
1995年 | 783篇 |
1994年 | 711篇 |
1993年 | 556篇 |
1992年 | 567篇 |
1991年 | 504篇 |
1990年 | 442篇 |
1989年 | 440篇 |
1988年 | 433篇 |
1987年 | 347篇 |
1986年 | 340篇 |
1985年 | 585篇 |
1984年 | 544篇 |
1983年 | 415篇 |
1982年 | 459篇 |
1981年 | 427篇 |
1980年 | 401篇 |
1979年 | 373篇 |
1978年 | 321篇 |
1977年 | 300篇 |
1976年 | 222篇 |
1975年 | 144篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的探讨慢性泪囊炎患者应用鼻内镜下鼻腔泪囊造口术的临床效果及安全性。方法选取2018年1月至2019年12月因慢性泪囊炎于本院接受治疗的46例患者为研究对象,随机分为研究组与对照组,各23例。对照组接受泪囊鼻腔造口治疗,研究组取鼻内镜下鼻腔泪囊造口术治疗,比较两组临床效果、手术指标以及并发症发生情况。结果研究组治疗总有效率高于对照组(P<0.05);研究组术中出血量少于对照组,手术及住院时间均短于对照组(P<0.05);研究组并发症总发生率低于对照组(P<0.05)。结论慢性泪囊炎患者采用鼻内镜下鼻腔泪囊造口术治疗效果显著,并发症较少,安全性较高,值得临床推广应用。 相似文献
3.
《Vaccine》2022,40(42):6048-6054
BackgroundLive vaccines potentially have non-specific effects that protect against other infections than those the vaccines are targeted against. The national vaccination program (NVP) in Finland was changed on September 1st, 2006: before BCG vaccine was given to all newborn babies and afterwards to babies in risk groups only. We used this natural experiment to study the non-specific effects of BCG in the frame of NVP using before-after design.MethodsWe compared the incidence of several outcomes obtained from Finnish health registers between children born between July 1st, 2004, and June 30th, 2006 (BCG-eligible) and an age- and season-matched reference cohort born between July 1st, 2007, and June 30th, 2009 (BCG-non-eligible) using Poisson regression. These cohorts were restricted to full-term children whose parents were born in Finland. Follow-up began at birth and lasted 3 months, which is the scheduled age for DTaP-IPV-Hib vaccination, and from 4 months until first birthday. The outcomes included all infections, pneumonia and injuries as a negative control outcome.ResultsThe incidence rate ratio (IRR) of the BCG-eligible cohort (N = 93,658) compared to BCG-non-eligible cohort (N = 94,712) for hospital-diagnosed infections was 0.89 (95 %Cl 0.86–0.93) for the 3-month follow-up. The decrease was mainly caused by respiratory infections. In 4–12 months follow-up the BCG-eligible had slightly more infections than BCG-non-eligible children (IRR 1.03, 1.01–1.06).ConclusionsBCG vaccination was associated with a lower incidence of all hospital-diagnosed infections during the first three months of life. The difference cannot be attributed to lung tuberculosis, since only few paediatric cases occurred in Finland during 2000s. The disappearance of non-specific effect after administration of an inactivated vaccine is compatible with previous studies. 相似文献
4.
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
8.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
9.
10.